Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
CTD2 researchers at Dana Farber identify that 2-oxoglutarate dehydrogenase, a tricarboxylic acid cycle enzyme, is crucial to maintain PIK3CA mutant tumor survival or proliferation.
Scientists demonstrate that Phosphoinositide 3-kinase enhancer (PIKE)-A directly interacts with CDK4. Furthermore, in vitro and in vivo studies in Glioblastoma (GBM) have shown that PIKE-A/CDK4 complex promotes cell proliferation and tumorigenesis.
Researchers developed a platform that integrates whole exome sequencing with high throughput drug screening in patient-derived tumor organoids. This platform has the potential to identify effective therapeutic strategies for patients where standard treatment options have been exhausted.
CTD2 scientists at Emory University have identified Aurora Kinase A as a novel H-Ras binding partner in enhancing MAPK signaling. This novel protein-protein interaction is a potential therapeutic target in cancer.
CTD2 researchers at University of Texas Southwestern identify marine bacteria-derived natural product N⁶,N⁶-dimethyladenosine as a potent inhibitor of Akt signaling in non-small cell lung cancer cell lines.
CTD2 scientists at CSHL characterize intratumoral heterogeneity of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Scientists at Dana Farber have performed CRISPR-Cas9 drug resistance screens and identified that loss of KEAP1 expression negates inhibitors targeting RTK/MAPK pathways in Lung cancer. This finding may assist with treatment decisions in managing lung cancer.
CTD2 researchers at Dana Farber have identified the transcription factor ATXN1-CIC-ETS as a mediator of resistance to MAPK inhibitors in KRAS mutant pancreatic cancer cell lines using genome-scale CRISPR-Cas9 loss-Of-function screens.
CTD2 scientists at Dana Farber have identified the serine/threonine kinase family member NEK6 as a central mediator in restoring sensitivity to hormone ablation in prostate cancer xenograft models.
The OncoPPi network is a resource of experimentally determined physical protein-protein interactions that builds on cancer genomics for discovery and exploitation of cancer vulnerabilities.